Get the Stockscreener App
1.74
1.75%
0.03
Actinium Pharmaceuticals Inc stock is traded at $1.74, with a volume of 122.72K.
It is up +1.75% in the last 24 hours and down -4.40% over the past month.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
See More
Previous Close:
$1.71
Open:
$1.73
24h Volume:
122.72K
Relative Volume:
0.41
Market Cap:
$54.28M
Revenue:
$1.05M
Net Income/Loss:
$-48.82M
P/E Ratio:
-0.9508
EPS:
-1.83
Net Cash Flow:
$-47.49M
1W Performance:
+2.96%
1M Performance:
-4.40%
6M Performance:
+48.72%
1Y Performance:
-14.71%
1-Day Range:
$1.72
$1.7899
1-Week Range:
$1.60
$1.7899
52-Week Range:
$1.06
$2.41
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.74 | 53.34M | 1.05M | -48.82M | -47.49M | -1.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
Will Actinium Pharmaceuticals Inc. see short term momentumPortfolio Performance Summary & Smart Money Movement Tracker - Newser
What to expect from Actinium Pharmaceuticals Inc. in the next 30 daysMarket Activity Recap & Entry Point Confirmation Signals - Newser
Can Actinium Pharmaceuticals Inc. hit a new high this monthJuly 2025 Spike Watch & High Return Trade Opportunity Guides - Newser
Reversal Traders Monitor Actinium Pharmaceuticals Inc. for EntryMarket Risk Analysis & Risk Controlled Daily Trade Plans - mustnews.co.kr
Will Actinium Pharmaceuticals Inc. rebound enough to break evenJuly 2025 Macro Moves & High Conviction Buy Zone Alerts - Newser
Will Actinium Pharmaceuticals Inc. price bounce be sustainableQuarterly Profit Review & Fast Exit and Entry Strategy Plans - Newser
How to manage a losing position in Actinium Pharmaceuticals Inc.Earnings Summary Report & Long-Term Growth Plans - Newser
How to track smart money flows in Actinium Pharmaceuticals Inc.2025 Trading Recap & Fast Gaining Stock Strategy Reports - Newser
What indicators show strength in Actinium Pharmaceuticals Inc.2025 Market Trends & AI Forecasted Entry and Exit Points - Newser
Does Actinium Pharmaceuticals Inc. qualify in momentum factor screeningRecession Risk & Low Risk Entry Point Tips - Newser
Sector ETF performance correlation with Actinium Pharmaceuticals Inc.2025 Investor Takeaways & Long-Term Safe Investment Plans - Newser
Predicting Actinium Pharmaceuticals Inc. trend using moving averagesJobs Report & Weekly Breakout Opportunity Watchlist - Newser
Will Volume Confirm Reversal in Actinium Pharmaceuticals Inc.July 2025 Summary & Technical Confirmation Alerts - newsyoung.net
Analyzing drawdowns of Actinium Pharmaceuticals Inc. with statistical toolsJuly 2025 PreEarnings & Consistent Profit Trading Strategies - Newser
Actinium Pharmaceuticals Inc.’s volatility index tracking explainedQuarterly Market Review & Verified Entry Point Signals - Newser
Visual analytics tools that track Actinium Pharmaceuticals Inc. performance2025 Sector Review & High Yield Stock Recommendations - Newser
Visualizing Actinium Pharmaceuticals Inc. stock with heatmaps2025 Top Gainers & Technical Pattern Alert System - Newser
Is Actinium Pharmaceuticals Inc. meeting your algorithmic filter criteria2025 Trading Recap & Weekly Watchlist for Hot Stocks - Newser
Can machine learning forecast Actinium Pharmaceuticals Inc. recoveryMarket Risk Analysis & High Accuracy Buy Signal Tips - Newser
What’s next for Actinium Pharmaceuticals Inc. stock priceTrade Entry Summary & Detailed Earnings Play Strategies - Newser
Actinium Pharmaceuticals Inc. recovery potential after sell offExit Point & Weekly Momentum Picks - Newser
Does Actinium Pharmaceuticals Inc. stock reflect fundamentalsWeekly Gains Report & AI Powered Market Entry Ideas - thegnnews.com
What institutional flow reveals about Actinium Pharmaceuticals Inc.Sell Signal & Precise Swing Trade Entry Alerts - Newser
Is Actinium Pharmaceuticals Inc. showing signs of accumulation2025 Market WrapUp & Verified Momentum Stock Watchlist - Newser
Has Actinium Pharmaceuticals Inc. formed a bullish divergenceJuly 2025 Review & Weekly Breakout Watchlists - Newser
Is Actinium Pharmaceuticals Inc. a Top Dividend Stock to Watch in 2025Earnings Recap Report & Fast Moving Stock Watchlists - Newser
Actinium Pharmaceuticals Inc. Price Targets Raised After ReboundWeekly Investment Recap & Community Consensus Trade Signals - beatles.ru
What moving averages say about Actinium Pharmaceuticals IncFree Swing Trade With Risk Management - Newser
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):